- CA$197.15m
- CA$128.17m
- $10.68m
- 55
- 13
- 55
- 35
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.36 | ||
| Price to Tang. Book | 2.37 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 13.32 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -51.93% | ||
| Return on Equity | -60.7% | ||
| Operating Margin | -309.57% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 7.3 | 6.87 | 6.68 | 7.2 | 10.68 | 18.09 | 42.38 | 20.67% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Profound Medical Corp. is a Canada-based commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. It is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), robotically driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low -, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (BPH); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. It is also commercializing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.
Directors
- Arun Menawat CHM (66)
- Aaron Davidson CFO (52)
- Rashed Dewan CFO (53)
- Mathieu Burtnyk VPR (39)
- Guruprit Singh VPR (55)
- Brian Ellacott NID (63)
- Kenneth Galbraith NID (59)
- Cynthia Lavoie NID (54)
- Murielle Lortie NID (51)
- Jean-Francois Pariseau NID
- Arthur Rosenthal NID (74)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- July 16th, 2014
- Public Since
- September 24th, 2014
- No. of Employees
- 131
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
Toronto Stock Exchange- Shares in Issue
- 30,053,142
- Address
- 2400 Skymark Ave Unit 6, MISSISSAUGA, L4W 5K5
- Web
- https://profoundmedical.com/
- Phone
- +1 6474761350
- Contact
- Stephen Kilmer
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for PRN
Q1 2025 Profound Medical Corp Earnings Release
Q1 2025 Profound Medical Corp Earnings Call
Profound Medical Corp Annual Shareholders Meeting
Profound Medical Corp Extraordinary Shareholders Meeting
Profound Medical Corp Annual Shareholders Meeting
Q2 2025 Profound Medical Corp Earnings Release
Similar to PRN
Bausch + Lomb
Toronto Stock Exchange
Healwell Al
Toronto Stock Exchange
Sernova Biotherapeutics
Toronto Stock Exchange
Vitalhub
Toronto Stock Exchange
FAQ
What is the Profound Medical share price?
As of Today at 22:45 UTC, shares in Profound Medical are trading at CA$6.56. This share price information is delayed by 15 minutes.
How has the Profound Medical share price performed this year?
Shares in Profound Medical last closed at CA$6.56 and the price had moved by -41.74% over the past 365 days. In terms of relative price strength the Profound Medical share price has underperformed the Toronto Stock Exchange 300 Composite Index by -48.2% over the past year.
What are the analyst and broker recommendations for Profound Medical?
The overall consensus recommendation for Profound Medical is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Profound Medical dividend yield?
Profound Medical does not currently pay a dividend.
Does Profound Medical pay a dividend?
Profound Medical does not currently pay a dividend.
When does Profound Medical next pay dividends?
Profound Medical does not currently pay a dividend.
How do I buy Profound Medical shares?
To buy shares in Profound Medical you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Profound Medical?
As of the previous close price of CA$6.56, shares in Profound Medical had a market capitalisation of CA$197.15m.
Where are Profound Medical shares listed?
Here are the trading details for Profound Medical:
- Country of listing: Canada
- Exchange: TOR
- Ticker Symbol: PRN
What kind of share is Profound Medical?
Based on an overall assessment of its quality, value and momentum Profound Medical is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Profound Medical share price forecast for 2025?
The analyst consensus target price for shares in Profound Medical is CA$25.75. That is 292.49% above the last closing price of CA$6.56.
Analysts covering Profound Medical currently have a consensus Earnings Per Share (EPS) forecast of -$1.11 for the next financial year.
Find out moreWhat is the trend in the Profound Medical share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Profound Medical. Over the past six months, its share price has underperformed the Toronto Stock Exchange 300 Composite Index by -35.37%.
As of the last closing price of CA$6.56, shares in Profound Medical were trading -38.02% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Profound Medical PE Ratio?
The Profound Medical PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$6.56.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Profound Medical?
Profound Medical's management team is headed by:
- Arun Menawat - CHM
- Aaron Davidson - CFO
- Rashed Dewan - CFO
- Mathieu Burtnyk - VPR
- Guruprit Singh - VPR
- Brian Ellacott - NID
- Kenneth Galbraith - NID
- Cynthia Lavoie - NID
- Murielle Lortie - NID
- Jean-Francois Pariseau - NID
- Arthur Rosenthal - NID